About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Oct 02, 2019...
The lungs of a mouse with untreated Ewing sarcoma (left) contain numerous tumor cells (shown by luminescent colors) that have spread from the bone; the lungs of a mouse treated with a drug reducing the synthesis of glucocorticoids are almost free from the sarcoma (right)
REHOVOT, ISRAEL—October 2, 2019—Ewing sarcoma is a bone cancer that appears mainly in teenagers. Caused by a single defective gene, once it spreads to distant organs it is hard to treat. Researchers at the Weizmann Institute of Science have now discovered molecular interactions underlying Ewing sarcomas and proposed a potential treatment that has shown promise in a study in mice. These findings were published in Cell Reports.
https://www.weizmann-usa.org/news-media/news-releases/ebola-antibodies-at-work/
Oct 07, 2019... In the recurring, deadly Ebola outbreaks in parts of Africa, today’s health workers now have at least some tools to fight the disease: vaccines. Vaccines against Ebola have been administered to over 100,000 people to date, but they are barely out of the experimental stage. It is not known how well these vaccines will provide long-term protection across a broad population. Furthermore, on the basic scientific level, the effects of vaccination on the immune system and how the immune response of vaccinated individuals compares with that of individuals who have survived Ebola infections was not known. A Weizmann Institute of Science lab recently joined forces with a research team in Cologne, Germany, to uncover the details of the molecular response that occurs in the immune system after vaccination against Ebola. Their findings may help health organizations devise better strategies for containing and preventing the disease.
Mar 23, 2020... Dr. Nir London of the Weizmann Institute’s Department of Organic Chemistry explains his lab’s approach to fighting the coronavirus: creating a novel antiviral treatment. After identifying candidates for an antibody, he and his team are designing second-generation compounds that will go to colleagues in Germany and the U.K. for testing against the virus. Dr. London emphasizes the fact that this is open science: research that is freely available to all, for the benefit of everyone.
Oct 07, 2019...
A group of Israeli and German scientists has joined forces to defeat Ebola, one of the deadliest contagious diseases of the 21st century.A Weizmann Institute of Science lab recently started to work with a research team in Cologne, Germany, to gain a better understanding of how the vaccination against the virus affects the immune system.
“These vaccines -- made by recombinant methods that attach an Ebola protein to a harmless virus -- are hard to produce, and thus there is not enough of them to vaccinate an entire population,” explained Ron Diskin of Weizmann’s Structural Biology Department.“In addition, the civil strife in some areas where Ebola is rampant today, the facts that it is often needed in villages that are hard to reach and that because of its scarcity, the vaccine tends to be given only to those most closely connected to individuals who are already sick,” he further stated.“Understanding exactly how the immune response is produced following vaccination will not only help refine the vaccine, itself. It can help us understand whether it will work against different strains of the virus or whether the dose given today is the best one,” the scientist added. The Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.According to the World Health Organization, the Ebola fatality rate is around 50%, but it can vary from 25% to 90% in different outbreaks.
Mar 19, 2020... “This is the most important thing I can do,” says the Weizmann Institute’s Prof. Sarel Fleishman. His lab in the Department of Biomolecular Sciences was already studying SARS, which is, like COVID-19, a coronavirus. He is able to quickly apply his knowledge to developing computer models that allow him to design coronavirus antibodies – work that could lead to a vaccine.
Mar 19, 2020... In this videoconference, the Weizmann Institute’s Dr. Ron Diskin of the Department of Structural Biology, an expert in animal-borne viruses such as coronavirus, shares his insights on the current pandemic. A Q&A session with participants follows.
https://www.weizmann-usa.org/news-media/news-releases/two-steps-ahead-of-the-coronavirus/
Mar 22, 2020... REHOVOT, ISRAEL—March 22, 2020—A method for monitoring, identifying, and predicting where the coronavirus will spread has attracted considerable international interest. It was initiated and developed by scientists from the Weizmann Institute of Science, in collaboration with researchers from the Hebrew University of Jerusalem and Clalit Health Services and in coordination with Israel’s Ministry of Health. Other governments have now begun to implement the method, which is based on questionnaires for the general public and analysis of the data obtained from them. The questionnaires track the development of virus-induced symptoms, and the analysis relies on Big Data algorithms and artificial intelligence. Viral spread occurs in clusters of infection; thus, early identification of clusters may facilitate various actions aimed at slowing down the spread of the virus.
Jan 22, 2020...
Israeli scientists have discovered the effect of a gene in causing epilepsy and autism, which may lead to new therapies, the Weizmann Institute of Science (WIS) reported Thursday.
In a study published in the journal Nature Communications, the WIS researchers examined a non-coding gene, which is not translated into protein but replicated into control molecules.
The researchers found that by releasing the grip of this gene from another gene that produces proteins, the genetic defect responsible for these diseases can be corrected.
Jan 13, 2020...
A group of scientists led by a team from the Weizmann Institute of Science has devised a decoy molecule that could lead to the treatment of viruses that cross over from animals to humans.
A host of disease-causing viruses, which are called arenaviruses, “lurk in animal populations in various parts of the world, sometimes crossing over into humans,” the Rehovot-based Weizmann Institute said in a statement. “When they do cross over, they can be lethal, and only very few treatments exist.”
Mar 25, 2020... In this videoconference hosted by Weizmann Canada, Prof. Sarel Fleishman of the Weizmann Institute’s Department of Biomolecular Sciences gives a progress report on his lab’s coronavirus research. The coronavirus is so named because it is covered in “spikes” that look like the sun’s corona; Prof. Fleishman seeks to bind and neutralize the spike proteins, thus stopping the virus.
©2022 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR